Development of Brilliant Blue G (BBG) as a new surgical dye for internal limiting membrane (ILM) staining and peeling in vitrectomy

**Target disease: retinal/vitreous diseases requiring peeling of the internal limiting membrane**

Department of Ophthalmology, Kyushu University Hospital

**Synopsis**

Currently, the of-label use of indocyanine green (ICG) for surgical adjuvant for staining of the internal limiting membrane is accepted in current vitrectomy. In this research project, in place of ICG, brilliant blue G (BBG250) is used as a surgical adjuvant in current vitrectomy. The clinical effect of BBG250 is then judged and its safety is evaluated. Since its invention by Kyushu University in 2004, BBG250 has been used as a standard treatment in Europe union. As demonstrated by the results of the domestic and overseas clinical studies conducted/reported so far, BBG250 stains accurately during surgery. BBG250 was approved and is marketed in Europe. It has been administered to more than 6000 patients but no approved adverse effects have been reported. In this research project, we have been finished an investigator initiated trial and obtain marketing approval in Japan. Application for drug approval is being prepared at present.

**Vitreous surgery using ILM-BLUE®(epiretinal membrane)**

**Intellectual property information**: patented

**Related keywords**: brilliant blue G, dye for ophthalmic surgery, internal limiting membrane staining/peeling, retinal/vitreous diseases